Ipsen shares fall back below their 167.40 € resistance and lose 2%
The Paris-based laboratory declines in a sharply lower Paris market. The stock had nevertheless touched an intraday high before giving back its gains.
A breakout above resistance quickly erased during the session
The Ipsen share price falls 1.97% to 164.10 €, while the SBF 120 loses 1.58% and the CAC 40 1.62%.
The stock had nevertheless broken above its 167.40 € resistance intraday, reaching a high of 168.10 €, before falling back below it. This failed breakout limits the day's decline, but the price remains above its 20-day moving average (MM20, a gap of 3.53%) and its 50-day moving average (MM50, a gap of 7.66%).
The 10.1% gain over one month and the 5.2% gain over three months are therefore still largely preserved.
The third-quarter guidance upgrade remains the reference point
Ipsen once again raised its annual revenue and margin growth targets in its nine-month results release on October 22, 2026. The group also flagged, among its risks, the early entry of a generic version of lanreotide in the fourth quarter, which would weigh on Somatuline sales.
On the outlook, two regulatory submissions are under way: Dysport for chronic and episodic migraine, and Iqirvo for primary biliary cholangitis. For the session, the 167.40 € level remains the one to watch.